Home Your basket
• Oto-rhino-laryngology and...
   Price 10.50 €
• Toxic nodular goitre asso...
   Price 5.50 €
• Voice prostheses: long-te...
   Price 10.50 €
• Phoniatric management of ...
   Price 8.50 €
• Combined transoral and su...
   Price 10.50 €
• Migraine, neurone and ves...
   Price 5.50 €
• Recurrent mandibular amel...
   Price 12.50 €
• Influence of Platelet Ric...
   Price 10.50 €
• Diagnostic value of fine-...
   Price 8.50 €
• Evaluation of the handica...
   Price 10.50 €
• Cataract surgery and its ...
   Price 10.50 €
• Quality of life before an...
   Price 10.50 €
• Velo-pharyngeal incompete...
   Price 14.00 €
• Newborn and infant nasal ...
   Price 5.50 €
• Covering of parotid and c...
   Price 14.00 €
• Periphery, central and ps...
   Price 10.50 €
• The pedicled musculo-cuta...
   Price 8.50 €
• The symphonix symposium u...
   Price 8.50 €
• The prevention of voice d...
   Price 10.50 €
• Vocal effectiveness in sp...
   Price 10.50 €
• Supra and infra hyoid mid...
   Price 10.50 €
• External otitis...
   Price 8.50 €
• Late metastasis from rena...
   Price 8.50 €
• Formant structures of vow...
   Price 10.50 €
• Post-operative evaluation...
   Price 10.50 €
• Laryngeal schwannomas...
   Price 5.50 €
• Observational study to as...
   Price 14.00 €
• Vertebro and cranio veino...
   Price 14.00 €
• Research in cancer : adva...
   Price 5.50 €
• Benign tumors of the nasa...
   Price 14.00 €
• Analysis of the possibili...
   Price 8.50 €
• Fibrous dysplasia, a case...
   Price 10.50 €
• International Conference ...
   Price 5.50 €
• Carotid body paragangliom...
   Price 8.50 €
• Notes on voice and speech...
   Price 8.50 €
• Objective analysis of pos...
   Price 8.50 €
• Prognostic value of mandi...
   Price 10.50 €
• Interest of MIBI scintigr...
   Price 10.50 €
• Protruding ears...
   Price 8.50 €
• Time-intensity trade of b...
   Price 10.50 €
• Parathyroid carcinoma: di...
   Price 5.50 €
• Mucoepidermoid carcinomas...
   Price 10.50 €
• Medical rhinoplasty: Rati...
   Price 10.00 €
• Non-Hodgkin's lymphoma of...
   Price 5.50 €
• Adenoid cystic carcinoma ...
   Price 5.50 €
• CT scan, MR imaging and a...
   Price 10.50 €
• Role of positron emission...
   Price 15.00 €
• Explorations of the velum...
   Price 14.00 €
• Association of thyroid he...
   Price 12.50 €
• Post-operative complicati...
   Price 10.50 €
• Going from the tube feedi...
   Price 8.50 €
• Fronto-ethmoidal fibrous ...
   Price 8.50 €
• Quality of life evaluatio...
   Price 10.50 €
• Mucus physiopathology, up...
   Price 12.50 €
• Autologous fat graft for ...
   Price 14.00 €
• Lipoma of the floor of th...
   Price 10.50 €
• Frontal sinus osteoma and...
   Price 5.50 €
• Efficacy and safety of mo...
   Price 10.50 €
• Nasal involvement in Croh...
   Price 10.50 €
• Metastatic angiosarcoma t...
   Price 5.50 €
• Diagnosis of non organic ...
   Price 8.50 €
• Cemento-ossifying fibroma...
   Price 8.50 €
• Transgender voice and com...
   Price 12.00 €
• The relevance of Choukrou...
   Price 10.50 €
• A rare and unusual cause ...
   Price 8.50 €
• Planned reconstruction af...
   Price 8.50 €
• Laryngeal neuroendocrin c...
   Price 5.50 €
• Adenoid cystic carcinoma ...
   Price 5.50 €
• A study of peristomal rec...
   Price 5.50 €
• The three-stage frontal f...
   Price 14.00 €
• Free novascularized bone ...
   Price 15.00 €
• Mucosal melanomas of the ...
   Price 8.50 €
• Bone anchored hearing aid...
   Price 8.50 €
• Teeth and sinuses...
   Price 8.50 €
• A study of the effects of...
   Price 14.00 €
• Otoplasty for prominent e...
   Price 8.50 €
• Idiopathic sudden deafnes...
   Price 10.50 €

Total Order 744.00 €

contents
2019
   N# 1 |
2018
   N# 1 | 2 | 3 | 4 | 5 |
2017
   N# 1 | 2 | 3 | 4 | 5 |
2016
   N# 1 | 2 | 3 | 4 | 5 |
2015
   N# 1 | 2 | 3 | 4 | 5 |
2014
   N# 1 | 2 | 3 | 4 | 5 |
2013
   N# 1 | 2 | 3 | 4 | 5 |
2012
   N# 1 | 2 | 3 | 4 | 5 |
2011
   N# 1 | 2 | 3 | 4 | 5 |
2010
   N# 1 | 2 | 3 | 4 | 5 |
2009
   N# 1 | 2 | 3 | 4 | 5 |
2008
   N# 1 | 2 | 3 | 4 | 5 |
2007
   N# 1 | 2 | 3 | 4 | 5 |
2006
   N# 1 | 2 | 3 | 4 | 5 |
2005
   N# | 1 | 2 | 3 | 4 | 5 |
2004
   N# 1 | 2 | 3 | 4 | 5 |
2003
   N# 1 | 2 | 3 | 4 | 5 |
2002
   N# 1 | 2 | 3 | 4 | 5 |
2001
   N# 1 | 2 | 3 | 4 | 5 |
2000
   N# | 1 | 2 | 3 | 4 | 5 |
1999
   N# 1 | 2 | 3 | 4 | 5 |
1998
   N# 1 | 2 | 3 | 5 |
1997
   N# 1 | 2 | 3 | 4 | 5 |
1996
   N# 4 | 5 |

Click on the number of the review to see the content
Teaching bulletin CME
List of all teaching bulletins CME.
Editor reading committee
Editor reading committee.
To publish...
Instructions for authors
Archives Press and Books
Select of books and press articles.
Mailing list
News information letter.
Subscription prices


If you wish to adjust the size of the displayed characters, click in the high menu on "Your account" and choose the desired size.



  Contents > Previous page > Article detail print Download
o Issue N# 1 - 2000 o

OTONEUROLOGY

The natural history of untreated vestibular schwannomas. Is there a role for conservative management ?


Authors : R. M. Walsh, A. P. Bath, M. L. Bance, A. Keller, C. H. Tator, J. A. Rutka (Toronto)

Ref. : Rev Laryngol Otol Rhinol. 2000;121,1:21-26.

Article published in english



Summary : Objective: the aim of this study was to investigate the natural history and outcome following the conservative management of a group of patients with unilateral vestibular schwannomas. Methods: 72 patients with a radiological diagnosis of unilateral vestibular schwannoma were managed conservatively because of poor general health, advanced age, patient preference, small tumour size, minimal symptoms, or tumour in the only / better hearing ear. All patients underwent serial magnetic resonance imaging for assessment of tumour growth, according to American Academy of Otolaryngology-Head & Neck Surgery guidelines (1995). The mean duration of follow-up was 37.8 months (range 12-194 months). Patients were deemed to have failed conservative management if there was evidence of continuous or rapid radiological tumour growth, and / or increasing symptoms or signs. Results : the mean tumour growth rate was 1.16 mm/year (range -0.75 to 9.65 mm/year). Approximately 83% of tumours grew at less than 2 mm/year. Significant tumour growth (total growth > 1 mm) was seen in 36.4%, no or insignificant growth (0 - 1 mm) in 50%, and negative growth (< 0 mm) in 13.6% of tumours. The growth rate of cerebellopontine angle (CPA) tumours (1.4 mm/year) was significantly greater than that of tumours limited to the internal auditory canal (IAC) (0.2 mm/year) (p = 0.001). Failure of conservative management, in which active treatment was required, occurred in 15.3%. The outcome of these patients appeared to be as favourable as those who underwent primary treatment, without a period of conservative management. The growth rate of tumours in patients who failed conservative management (4.2 mm/year) was significantly greater than that in patients who did not fail (0.5 mm/year) (p < 0.01). No factors predictive of tumour growth were identified. Deterioration of mean pure tone average (0.5, 1, 2, 3 kHz) and speech discrimination scores occurred regardless of whether radiological tumour growth was demonstrated or not. Conclusions: The majority of vestibular schwannomas are slow growing, although, CPA tumours appear to grow faster than IAC tumours. Deterioration of auditory function occurs even in the absence of tumour growth. Although most Otolaryngologists and Neurosurgeons would agree that the treatment of choice for the majority of vestibular schwannomas is microsurgery, there remains a small group of patients in whom a conservative management approach may be a desirable alternative.


|


Subscribe online - Pay by credit card!


© Copyright 1999-2024 - Revue de Laryngologie   Réalisation - Hébergement ELIDEE